New recommendations aim to eliminate racial bias in myeloma trials

(Dana-Farber Cancer Institute) Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.